Bedrijfsoverzicht
Vicarious Surgical Inc. is a specialized developer and vendor focused on the creation and commercialization of single-port surgical robotics specifically designed for the United States healthcare market. The entity operates within the broader Healthcare sector, with its specific classification falling under the Medical Devices industry, an environment where technological innovation often precedes widespread market adoption. The company's current scale is defined by a market capitalization of $4.99 million and an operational team consisting of 26 employees, reflecting a very small-cap, early-stage enterprise. These valuation figures, combined with the lack of reported annual revenue, indicate that the company remains in a pre-commercialization or early revenue generation phase where capital allocation is directed toward product development rather than scaling existing sales operations.
Financiële gezondheid
The company's financial statements for the trailing twelve months report a revenue figure listed as N/A, while the net income stands at a significant loss of $-50,182,000 and EBITDA is reported at $-49,543,000. The substantial gap between the reported N/A revenue and the deep net losses reveals a cost structure dominated by research, development, and administrative overheads that far exceed any current operational cash inflows from sales. Vicarious Surgical Inc. generated a free cash flow of $-26,117,000, which indicates a negative financial flexibility where cash burn rates are currently funded by existing reserves rather than operational profitability. All three key margin metrics—gross margin, operating margin, and profit margin—are reported at 0.0%, a figure that suggests the company has not yet achieved positive profitability on its sales or cost basis, typical for firms in the initial scaling stages. On the balance sheet, the company holds $9.79 million in cash against $7.79 million in debt, resulting in a debt-to-equity ratio of 79.16, which characterizes a highly leveraged position relative to equity but suggests manageable absolute debt levels given the cash on hand. The current ratio is calculated at 2.97, indicating that the company possesses nearly three times more current assets than current liabilities, which points to a robust short-term liquidity position capable of meeting obligations without immediate distress. Return on Equity is recorded at -177.5% and Return on Assets at -73.0%, metrics that demonstrate that management is currently generating negative returns on the capital invested by shareholders and the total asset base, reflecting the high risk associated with developing proprietary surgical technology without established revenue streams.
Waarderingsbeoordeling
The trailing P/E ratio is N/A due to the absence of positive earnings, while the forward P/E is reported at -0.32, a negative figure that implies the market is pricing in future earnings expectations that may eventually turn positive, though the current trajectory is not profitable. The price-to-book ratio stands at 0.51, indicating that the stock is trading at a discount to its book value, which often occurs in small-cap biotech or medtech firms where current assets do not yet reflect the future value of intellectual property or pipeline potential. Alternative valuation metrics such as the price-to-sales ratio and EV/EBITDA are also unavailable or negative, with EV/EBITDA listed at -0.06, suggesting that traditional multiple-based comparisons to mature peers are not applicable at this stage of the company's lifecycle. The stock has experienced significant volatility, trading between a 52-week low of $0.27 and a 52-week high of $13.75, placing the current market price in a range that reflects high speculation and sentiment-driven pricing rather than fundamental earnings support. The beta value of 1.82 indicates that the stock is significantly more volatile than the broader market, moving with greater intensity to market swings, which is a characteristic trait of small-cap healthcare companies with limited market capitalization.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, meaning there is insufficient historical financial data to calculate a growth rate or determine if earnings are expanding faster than revenue. As a non-dividend payer, Vicarious Surgical Inc. maintains a dividend yield of N/A and a payout ratio of 0.0%, confirming that the company does not distribute profits to shareholders but instead retains all resources to fund operations and research initiatives. Because the company reinvests its limited cash flow into product development rather than paying dividends, the overall growth and income profile is entirely speculative, relying on the future commercial success of the single-port surgical robot to transition from a cash-burning entity to a revenue-generating business. This profile aligns with that of early-stage medical device companies where capital preservation is secondary to achieving product-market fit and securing regulatory approvals necessary to enter the commercial market.